Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | STS | P08842 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216027 | 1.00 | LMNA (0.58) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL19226865 | 1.00 | LMNA (0.58) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216878 | 0.94 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL216877 | 0.94 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL5022388 | 0.94 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738541 | 0.94 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL5016579 | 0.93 | LMNA (0.55) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738538 | 0.93 | LMNA (0.55) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL16384493 | 0.92 | LMNA (0.57) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL2738544 | 0.91 | LMNA (0.56) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105518016-B | Therapeutically active estratriene thiazole derivatives as 17 beta-hydroxysteroid dehydrogenase type 1 inhibitors | 佛恩多制药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-105518017-B | Therapeutically active estratriene thiazole derivatives as inhibitors of 17 β -hydroxysteroid dehydrogenase type 1 | 佛恩多制药有限公司 | 2020-07-14 | — | — | CN | disclosed |
| EP-3013845-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2020-03-18 | — | — | EP | disclosed |
| EP-3013847-B1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2019-08-21 | — | — | EP | disclosed |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2019-08-13 | — | — | US | disclosed |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2019-08-13 | — | — | US | disclosed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | disclosed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | disclosed |
| US-9850272-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 | FORENDO PHARMA LTD. (FI) | 2017-12-26 | — | — | US | disclosed |
| EP-3013846-B1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2017-08-09 | — | — | EP | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | FORENDO PHARMA LTD (FI) | 2017-03-23 | — | — | US | disclosed |
| WO-2014207309-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17 B-HYDROXYSTEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207311-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA.-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | FORENDO PHARMA LTD (FI) | 2014-12-31 | — | — | WO | disclosed |
| US-8088758-B2 | 17β-hydroxysteroid dehydrogenase type I inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192263-A1 | 3,15-substituted estrone compounds; treatment of steroid hormone dependent diseases such as breast cancer, colon cancer, endometriosis, benign prostatic hyperplasia | HSD17B11, HSD17B1, HSD17B3 | LMNA 2693/4885HSD17B1 2/4885MAPT 3025/4885 |
| US-20170081357-A1 | THERAPEUTICALLY ACTIVE 17-NITROGEN SUBSTITUTED ESTRATREINTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXYSTEROID DEHYDROGENASE | HSD17B11, HSD17B1, HSD17B3 | LMNA 2985/4885HSD17B1 2/4885MAPT 2574/4885 |
| US-10377791-B2 | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 | HSD17B1, HSD17B11, HSD17B3 | LMNA 3383/4885HSD17B1 1/4885MAPT 2310/4885 |
| US-20170081356-A1 | THERAPEUTICALLY ACTIVE ESTRATRIENTHIAZOLE DERIVATIVES AS INHIBITORS OF 17.BETA-HYDROXY-STEROID DEHYDROGENASE, TYPE 1 | HSD17B11, HSD17B1, HSD17B3 | LMNA 3881/4885HSD17B1 2/4885MAPT 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.